MIST

Milestone Pharmaceuticals Inc.
CAPPED RATING

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc. (MIST) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
B+
Factor Score 3.5 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.8
EV / EBITDA -0.8
Rev Growth YoY N/A
Gross Margin 98.0%
Price Return 3M -40.5%
Price Return 12M -65.7%
Catalyst Signal 0.00
Market Cap $81.6M
TTM Revenue $2.3M
Price / Sales 34.8
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.8) B+ (3.5) C (2.4) D (1.3) C+ (2.6) C+ (2.5)
2026-11-06 C+ (2.8) B (3.5) C (2.4) D- (1.1) C+ (2.7) C (2.5)
2026-10-30 C+ (2.8) B (3.5) C (2.4) D (1.4) C+ (2.7) C+ (2.5)
2026-10-23 C+ (2.8) B (3.4) C (2.4) D- (1.1) C+ (2.6) C (2.5)
2026-10-16 C+ (2.8) B (3.5) C (2.4) D (1.3) C+ (2.6) C (2.5)
Page 1 of 5